Organization | Public Health England

Public Health England Report issue

Government Phase 1 Phase 2 Phase 3 Phase 4

Founded: London United Kingdom (2013)

Organization Overview

First Clinical Trial

2013

NCT00197769

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Dr. Elizabeth Miller | Prof. Elizabeth Miller | Public Health England

Active Ingredients

Drugs in Phase 4 Trials (23)

4cmenb vaccine (1 trial)

azithromycin (zithromax) (2 trials)

boostrix (1 trial)

clindamycin (cleocin) (1 trial)

fluarix (1 trial)

flucloxacillin (1 trial)

fluenz (1 trial)

fluenz tetra (1 trial)

hib conjugate vaccine (1 trial)

hpv 16/18 vaccine (Cervarix) (1 trial)

human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant (Gardasil) (1 trial)

live attenuated influenza virus vaccine (flumist) (5 trials)

menb (4 trials)

menitorix (2 trials)

menjugate (2 trials)

nasovac-s (1 trial)

neisvac-c (2 trials)

pneumococcal 13-valent conjugate vaccine (prevnar 13) (1 trial)

quadrivalent groups a, c, y, and w-135 meningococcal vaccine (Menomune-A/C/Y/W-135) (3 trials)

repevax (2 trials)

synflorix (1 trial)

technetium tc-99m pentetate kit (renotec) (1 trial)

Drugs in Phase 3 Trials (6)

ad26.zebov (1 trial)

human papillomavirus 9-valent vaccine, recombinant (Gardasil 9) (1 trial)

menacwy conjugate vaccine (1 trial)

menafrivac (1 trial)

mva-bn-filo (1 trial)

s. aureus type 5 & 8 capsular polysaccharide conjugate (1 trial)

Drugs in Phase 2 Trials (12)

9 valent pneumococcal conjugate vaccine (1 trial)

aflunov (1 trial)

inactivated influenza vaccine (5 trials)

menbvac (1 trial)

menc/hib vaccine (1 trial)

multi-valent pneumococcal conjugate vaccine (1 trial)

pneumococcal 7-valent conjugate vaccine (prevnar) (1 trial)

prp antigen (1 trial)

serogroup b meningococcal vaccine (1 trial)

Drugs in Phase 1 Trials (2)

potassium alum (1 trial)

supraene (1 trial)

Drugs in Other Trials (1)

neisseria lactamica (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Asthma (Phase 4)

Cellulitis (Phase 4)

Communicable Diseases (Phase 4)

Diphtheria (Phase 4)

Egg Hypersensitivity (Phase 4)

Hemorrhagic Fever, Ebola (Phase 3)

Hepatitis (Phase 4)

Hepatitis B (Phase 4)

Hypersensitivity (Phase 4)

Infections (Phase 4)

Influenza, Human (Phase 4)

Meningitis (Phase 4)

Meningitis, Meningococcal (Phase 3)

Meningococcal Infections (Phase 4)

Papillomavirus Infections (Phase 4)

Pneumococcal Infections (Phase 4)

Pneumonia (Phase 2)

Premature Birth (Phase 4)

Staphylococcal Infections (Phase 3)

Virus Diseases (Phase 3)

Whooping Cough (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 41
# of Trial APIs: 44